Claire Harrison, MD

home / authors / claire-harrison-md

Articles

Expert on PV

Ruxolitinib Versus Best Available Therapy for Polycythaemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomised Trial

Claire Harrison, MD
June 20th 2023

Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).

Read More

Claire Harrison, MD, FRCP, FRCPath

Dr. Harrison on Unmet Needs in Myelofibrosis

Claire Harrison, MD
January 19th 2022

Claire Harrison, MD, FRCP, FRCPath, discusses current unmet needs in myelofibrosis.

Read More

Claire Harrison, MD, FRCP, FRCPath

Dr. Harrison on the Current State of Treatment in Myelofibrosis

Claire Harrison, MD
December 1st 2021

Claire Harrison, MD, FRCP, FRCPath, discusses the current state of treatment in myelofibrosis.

Read More

Dr. Harrison on 5-Year Follow-Up Data on Ruxolitinib in Patients With Myelofibrosis

Dr. Harrison on 5-Year Follow-Up Data on Ruxolitinib in Patients With Myelofibrosis

Claire Harrison, MD
December 6th 2015

Claire Harrison, MD, deputy clinical director of Cancer and Hematology, Guy's and St. Thomas' NHS, discusses 5-year follow-up data examining ruxolitinib in patients with myelofibrosis.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need